Targeting nodal in malignant melanoma cells

Lynne Marie Postovit, Elisabeth A. Seftor, Richard E.B. Seftor, Mary J.C. Hendrix*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


Metastatic melanoma continues to be a significantly deadly cancer with a cure rate of < 20% and a median survival of 6 - 9 months. The aggressiveness associated with metastatic melanoma is largely attributable to its inherent plasticity, a property that is mediated by the secretion of Nodal, a stem-cell associated protein belonging to the transforming growth factor-β super-family. This is supported by the observations that Nodal expression is limited to invasive vertical growth phase and metastatic melanoma lesions, and that inhibition of Nodal signaling promotes the reversion of metastatic melanoma cells toward a more differentiated, less invasive non-tumorigenic phenotype. Hence, due to its restricted expression pattern and function as a melanoma-tumor-promoter, Nodal (and its signaling partners) present unique targets for both immunologic and pharmacologic therapies.

Original languageEnglish (US)
Pages (from-to)497-505
Number of pages9
JournalExpert Opinion on Therapeutic Targets
Issue number4
StatePublished - Apr 2007


  • Cripto
  • Immunotherapy
  • Lefty
  • Melanoma
  • Metastasis
  • Nodal
  • Notch
  • Stem cell

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine
  • Clinical Biochemistry
  • Pharmacology


Dive into the research topics of 'Targeting nodal in malignant melanoma cells'. Together they form a unique fingerprint.

Cite this